Nimisha Trivedi, MD
Family Medicine · Locust Grove, GANPI 1629074299
Payments from drug & device makers
Across 542 payments — averaging $29.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$5K
- AstraZeneca$2K
- Novo Nordisk$1K
- AbbVie$1K
- Bayer$931
- GSK$807
- plus $5K from 29 others
What the payments were for
- Food & beverage$10,55599%
- Education$1341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 5 | $5,455 |
| AstraZeneca | 62 | $1,851 |
| Novo Nordisk | 78 | $1,317 |
| AbbVie(2 entities) | 79 | $1,250 |
| Bayer | 27 | $931 |
| GSK | 33 | $807 |
| Lilly USA, LLC | 50 | $767 |
| Amgen(2 entities) | 45 | $720 |
| Pfizer | 18 | $328 |
| Shield Therapeutics Inc | 14 | $299 |
| Boehringer Ingelheim | 18 | $262 |
| Novartis | 10 | $201 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $197 |
| Phathom Pharmaceuticals, Inc. | 7 | $192 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $163 |
| Astellas Pharma US Inc | 5 | $162 |
| Kowa Pharmaceuticals America, Inc. | 9 | $157 |
| Amarin Pharma, Inc. | 8 | $154 |
| Biohaven Pharmaceuticals, Inc. | 10 | $126 |
| Exact Sciences | 5 | $110 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $98 |
| Sanofi-aventis U.S. LLC | 6 | $92 |
| Medtronic | 2 | $89 |
| Corcept Therapeutics | 3 | $86 |
| Teva Pharmaceuticals USA, Inc. | 4 | $51 |
| Merck | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Mylan Specialty L.p. | 2 | $35 |
| Verona Pharma, Inc. | 2 | $29 |
| Radius Health, Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Linus Health, Inc. | 1 | $14 |
| Optos, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,143 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 310 | $351,779 |
| FarxigaDapagliflozin Propanediol | 180 | $219,074 |
| KerendiaFinerenone | 128 | $155,273 |
| OzempicSemaglutide | 110 | $140,443 |
| MounjaroTirzepatide | 105 | $124,288 |
| TrulicityDulaglutide | 98 | $114,289 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 101 | $110,628 |
| RybelsusSemaglutide | 51 | $103,880 |
| LinzessLinaclotide | 98 | $68,763 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 49 | $64,677 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 59 | $63,973 |
| TradjentaLinagliptin | 50 | $57,581 |
| EliquisApixaban | 61 | $56,123 |
| Xigduo XrDapaglifloz Propaned/Metformin | 47 | $45,826 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $30,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr, Glyxambi | $262 | $498,523445 claims |
| Novo NordiskOzempic, Rybelsus | $1,317 | $244,323161 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,851 | $239,621228 claims |
| Lilly USA, LLCMounjaro, Trulicity | $767 | $238,577203 claims |
| BayerKerendia | $931 | $155,273128 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix | $807 | $147,552182 claims |
| MerckJanumet Xr, Januvia, Janumet, Belsomra | $49 | $105,74591 claims |
| AbbVieLinzess, Vraylar | $1,250 | $88,783110 claims |
| PfizerEliquis, Nurtec Odt | $328 | $77,93676 claims |
| Astellas Pharma US IncMyrbetriq | $162 | $21,89740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Locust Grove
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.